Catherine Bollard
14
2
6
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
13%
1 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903
Role: lead
Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma
Role: lead
Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL)
Role: lead
Allogeneic Virus-specific T Cell Lines (VSTs)
Role: lead
Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
Role: lead
Multi-antigen T Cell Infusion Against Neuro-oncologic Disease
Role: lead
HIV-1 Specific T -Cells (HST-NEETs) for HIV-Infected Individuals
Role: lead
Evaluate the Safety, Immunologic, and Virologic Responses of Donor Derived (DD) HIV-Specific T-cells (HST) in HIV-infected Individuals Following Allogeneic Bone Marrow Transplantation (alloRESIST)
Role: lead
Mesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP)
Role: lead
Haploidentical Hematopoietic Stem Cell Transplantation
Role: lead
Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma
Role: lead
Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis
Role: lead
Safety and Tolerability Of Allogeneic Mesenchymal Stromal Cells in Pediatric Inflammatory Bowel Disease
Role: lead
Multivirus-specific Cytotoxic T Lymphocytes (mCTL)
Role: lead
All 14 trials loaded